Companies / Moderna
MRNAModerna
1 active clinical study registered on ClinicalTrials.gov, the most advanced in Phase 1/2.
Programmes
| Programme | Most advanced | Conditions | Partner | Sources | Checked |
|---|---|---|---|---|---|
| VX-522 VX-522 mRNA therapy |
Phase 1/2? | Cystic Fibrosis | Vertex Pharmaceuticals Incorporated | NCT05668741 | 27 October 2026 |
Clinical studies
| Primary completion | Phase | Status | Condition and study |
|---|---|---|---|
| 21 Apr 2026 passed |
Phase 1/2? | Active, not recruiting | Cystic Fibrosis A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) · NCT05668741 |
Source: ClinicalTrials.gov, studies with the company as sponsor and an active status. Data fetched 7 October 2026.
Recent news
Headlines from other publications, linked to the original. We do not rewrite or summarise them. Analyst ratings and price targets are the opinion of the cited source, not ours.
- Novavax, Moderna stocks fall after WHO calls plague risk 'low'
- Biotechs Sell Off — These Are The Biggest Losers
- Stocks making the biggest moves midday: Marvell, Moderna, Lamb Weston, Constellation Energy & more
- Why is Moderna stock sliding today?
- Why Is Moderna Stock (MRNA) Falling Today, October 6?
- MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail Echoes Valuation Concerns
- Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
- Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna and Pfizer Inch Higher
- Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?
- Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?
- NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
- Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips